Panther is developing a proprietary dissolvable microneedle array patch (MAP) that delivers targeted treatments to the skin's immune-rich layers, enhancing systemic immune responses with reduced side effects. This technology addresses the challenges of under-vaccination and the high cost of immune-related disease treatments by providing safer and more accessible options.
Funding
Funding not disclosed
Founders
Product
Problem
Current vaccination methods often suffer from limitations in accessibility, leading to under-vaccination rates globally. Traditional treatments for immune-related diseases can be expensive and may produce undesirable side effects, hindering widespread availability and patient compliance.
Solution
Panther is developing a dissolvable microneedle array patch (MAP) designed to deliver targeted treatments directly to the skin's immune-rich layers. This approach aims to enhance systemic immune responses while minimizing side effects compared to conventional methods. The MAP platform delivers treatments in solid state to precise locations within the dermis and epidermis, where a high concentration of immune cells resides, facilitating effective treatment pathways. Panther's technology seeks to provide better, safer, and more affordable treatments, increasing accessibility and improving patient outcomes.
Target Audience
The primary target audience includes individuals requiring vaccinations, patients with immune-related diseases, and healthcare providers seeking more effective and accessible treatment options.
Features
- Proprietary dissolvable microneedle array patch (MAP) for targeted drug delivery.
- Solid-state delivery of treatments to specific skin layers (dermis, epidermis).
- Designed to activate systemic immune responses with enhanced efficacy.
- Potential for reduced or eliminated side effects compared to current methods.
- Disposable device for ease of use and improved hygiene.
- Platform technology applicable to a range of immune-related diseases.